Contract sales organization PDI has created a new business unit, Interpace BioPharma, as part of its strategy for managing new commercial platforms. Interpace is structured to “provide the flexibility for additional fee-for-service agreements and other product commercialization opportunities,” according to a PDI statement. Interpace BioPharma has entered into a two-and-a-half-year, fee-for-service agreement with a pharmaceutical company to market a treatment for knee pain in the U.S...